University of Southern California

Research

USC Stem Cell Research Oversight Committee (SCRO)

The SCRO reviews, approves, and provides oversight over all issues related to the derivation and use of human pluripotent stem cells as defined by federal and state law. Research under the SCRO’s jurisdiction may not commence until approved by the SCRO.

SCRO review is not required for non-human cells, and is not required if cells are not pluripotent.

SCRO’s review is limited to review and approval for appropriate use of stem cells in the following circumstances:

The SCRO also is empowered to monitor, audit, suspend and/or terminate research covered in this section.

Review by SCRO does not substitute for reviews that may be required by the Institutional Review Board (IRB)Institutional Animal Care and Use Committee (IACUC) or the Institutional Biosafety Committee (IBC).

Process for Submitting Proposals

Investigators with new proposals must complete the SCRO’s New Proposal Application and include a copy of the proposal submitted to the proposed funding agency. The SCRO may request additional information from the investigator(s) as deemed necessary to review the proposal in accordance with regulatory requirements.

Investigators must submit a Continuing Review Application at least annually or more frequently, as determined by the SCRO. The SCRO may request additional information from the investigator(s) as deemed necessary to review the proposal in accordance with regulatory requirements.

SCRO applications should be submitted electronically to the committee chair, David Hinton, SCRO Chair dhinton@usc.edu.

Below are some forms:

  1. SCRO New Proposal Application
  2. SCRO Continuing Review Application
  3. Request to Add New Stem Cell Lines

Review Process

The following types of applications are reviewed by the full SCRO, which meets approximately once per month:

Annual continuing reviews for studies that have no or minor changes from the original application (as determined by the SCRO chair or designated approver) may be reviewed and approved administratively by the committee chair.

A decision is normally made within 30 days of application.

For More Information, Contact:

Vicky Fox, Core Director, victoria.fox@keck.usc.edu

David Hinton, SCRO Chair, dhinton@usc.edu

Resources

Definitions

“Covered stem cells”: Defines the SCRO’s jurisdiction. A “covered stem cell line” means a culture-derived, human pluripotent stem cell population that is capable of: (1) sustained propagation in culture; and (2) self-renewal to produce daughter cells with equivalent developmental potential. This definition includes both embryonic and non-embryonic human stem cell lines, regardless of the tissue of origin.

“Pluripotent”: Means capable of differentiation into mesoderm, ectoderm and endoderm.

“Human embryonic stem cells”: Defined as pluripotent stem cells derived from the inner cell mass of pre-implantation blastocysts. They are defined by their ability to proliferate for prolonged periods in vitro as an undifferentiated population and to differentiate into adult cell types representing all three embryonic germ layers.

“Human embryonic germ cells”: Defined as pluripotent stem cells derived from primordial germ cells isolated from the gonadal ridges of five to ten week old human embryos. They are capable of sustained self renewal in vitro and differentiation into adult cell types representing all three embryonic germ layers.

“Induced Pluripotent Stem Cells (iPSCs)”: Defined as a type of pluripotent stem cell generated from somatic cells by enforcing the expression of reprogramming genes. They are capable of prolonged self renewal in vitro and differentiate to make cell types corresponding to all three embryonic germ layers.